Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo
Authors:
Open Access
- 10 March 2023
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 185, 106422
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Molecular Insight into the Steric Shielding Effect of PEG on the Conjugated Staphylokinase: Biochemical Characterization and Molecular Dynamics SimulationPLOS ONE, 2013
- A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivoJournal of Pharmacy and Pharmacology, 2012
- Transferrin Fusion Technology: A Novel Approach to Prolonging Biological Half-Life of Insulinotropic PeptidesThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Efficient Tumor Targeting with High-Affinity Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular SizeCancer Research, 2010
- A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable mannerNature Biotechnology, 2009
- DARPins: A new generation of protein therapeuticsDrug Discovery Today, 2008
- An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose HomeostasisGastroenterology, 2008
- Obesity and Diabetes in the Developing World — A Growing ChallengeNew England Journal of Medicine, 2007
- Using circular dichroism spectra to estimate protein secondary structureNature Protocols, 2006
- Insulin resistance, lipid and fatty acid concentrations in 867 healthy EuropeansEuropean Journal of Clinical Investigation, 2000